Toppharma Marketing (M) Sdn. Bhd. (TOPPHARMA) is a pharmaceutical service and marketing company having an international network of pharmaceutical companies with experience in collaboration to do multi-centre clinical trial study, warehousing and distribution of vaccines, biological and medical products to private and public sectors. In line with the company's commitment to excellence and sustainable relationship in the healthcare industry, we will continue to be innovative in our pharmaceutical services and continuous assurance in providing safe and quality products to our clients and consumers.

TOPPHARMA and IMBCAMS has entered into an Exclusive Agency Agreement to authorize TOPPHARMA as the exclusive agent and sole distributor and product(license) registration holder in Malaysia.

Institute of Medical Biology Chinese Academy of Medical Sciences (IMBCAMS) is a state owned enterprise, China's Public Institutional Organization with direct association with the National Health Commission of the People's Republic of China and Chinese Academy of Medical Sciences Peking Union Medical College.

IMBCAMS is founded in August 1958 in Yunnan Province of China to combat infectious diseases worldwide. IMBCAMS integrates basic medical research, postgraduate education with development and production of biological products. The institution is master’s and doctor’s degree conferring unit of the Peking Union Medical College (the Medical School of Tsinghua University), as well as the innovative research and production base for poliomyelitis vaccines, Hepatitis A vaccines, and vaccines against Hand, Foot and Mouth Disease (HFMD) in China. IMBCAMS has invented five vaccines against major infectious diseases, which has become one of the lead vaccine manufacturers to achieve the target of developing new vaccines in China.

Since the early COVID-19 virus pandemic, the IMBCAMS scientists has researched and developed the SARS-CoV-2 Vaccine, Inactivated and is conducting the ongoing multi-centre Phase 3 clinical trial in Brazil, China, Malaysia, Mexico, and Bangladesh which involves 34,020 subject volunteers. On 1^st May 2021, IMBCAMS's COVID-19 vaccine, ICORNVAC^TM, has been authorized for Emergency Use Listing (EUL) by the Working Group for Vaccine Development Under the State Council Joint Prevention and Control Mechanism Against COVID-19 of China.

In the near future, IMBCAMS will constantly improve the vaccine innovation ability and fasten the steps to internationally standardize manufacturing capacity, provide vaccines targeting international market and devote to the goal of creating human health globally.